received approval from the
Food and Drug Administration
to commercially release a new version of the company's implantable cardioverter-defibrillators.
The defibrillators are used to try to prevent heart attacks and other cardiac problems. The new product is called the Medtronic GEM III DR ICD.
Shares of Medtronic recently gained 50 cents, or 0.9%, to $55.44 in
New York Stock Exchange